Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H18N2O5 |
| Molecular Weight | 294.3031 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CC(O)=O
InChI
InChIKey=IAOZJIPTCAWIRG-QWRGUYRKSA-N
InChI=1S/C14H18N2O5/c1-21-14(20)11(7-9-5-3-2-4-6-9)16-13(19)10(15)8-12(17)18/h2-6,10-11H,7-8,15H2,1H3,(H,16,19)(H,17,18)/t10-,11-/m0/s1
| Molecular Formula | C14H18N2O5 |
| Molecular Weight | 294.3031 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Aspartame (l-aspartyl-l-phenylalanine methyl ester) known to the public as NutraSweet has been the subject of controversy since it first became an ingredient in food products. The perceived sweetness of aspartame in humans is due to its binding of the heterodimer G-protein coupled receptor formed by the proteins TAS1R2 and TAS1R3. Aspartame was used in experiments on animals to study its role in delays of osteoarthritis. It was shown, that aspartame improved bone cortical density and muscle mass, and might contribute to a better quality of life for these diseased animals. In addition, was investigated the effect in patients with sickle cell anemia. It was revealed, that oral administration of aspartame lead inhibition of sickle cells. That effect was explained by binding aspartame with two human Bence Jones proteins: Mcg and Sea. Thus was suggested, that aspartame could interfere with sickle hemoglobin fibril formation. Then several studies showed that aspartame had no effect on the polymerization of sickle hemoglobin.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q8TE23 Gene ID: 80834.0 Gene Symbol: TAS1R2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11917125 |
|||
Target ID: Q7RTX0 Gene ID: 83756.0 Gene Symbol: TAS1R3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11917125 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Canderel Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Aspartame and aspartame derivatives effect human thrombin catalytic activity. | 2004-12-20 |
|
| Influence of strawberry yogurt composition on aroma release. | 2004-10-06 |
|
| Aspartame and its effects on health. | 2004-10-02 |
|
| Flow-through spectrophotometric sensor for the determination of aspartame in low-calorie and dietary products. | 2004-10 |
|
| Effect of concentration on taste-taste interactions in foods for elderly and young subjects. | 2004-10 |
|
| Artificial sweeteners--do they bear a carcinogenic risk? | 2004-10 |
|
| Different functional roles of T1R subunits in the heteromeric taste receptors. | 2004-09-28 |
|
| Genotoxicity of aspartame. | 2004-08 |
|
| Oral zinc sulfate solutions inhibit sweet taste perception. | 2004-07 |
|
| Acetaminophen-containing chewable tablets with suppressed bitterness and improved oral feeling. | 2004-06-18 |
|
| Synthesis and characteristics of an aspartame analogue, L-asparaginyl L-3-phenyllactic acid methyl ester. | 2004-06 |
|
| Effects of short-chain fructo-oligosaccharides on glucose and lipid metabolism in mild hypercholesterolaemic individuals. | 2004-06 |
|
| Chronic aspartame affects T-maze performance, brain cholinergic receptors and Na+,K+-ATPase in rats. | 2004-05 |
|
| Receptors for bitter, sweet and umami taste couple to inhibitory G protein signaling pathways. | 2004-04-12 |
|
| The effects of nicotine and sucrose on spatial memory and attention. | 2004-04 |
|
| The brain-cancer puzzle. | 2004-04 |
|
| Dietary estimated intake of intense sweeteners by Italian teenagers. Present levels and projections derived from the INRAN-RM-2001 food survey. | 2004-04 |
|
| [Adverse effect of aspartame--does it exist?]. | 2004-03-18 |
|
| Aspartame has no effect on the polymerization of sickle hemoglobin. | 2004-03 |
|
| Effect of four-day psyllium supplementation on bowel preparation for colonoscopy:A prospective double blind randomized trial [ISRCTN76623768]. | 2004-02-02 |
|
| The influence of fat co-administration on the glucose memory facilitation effect. | 2004-02 |
|
| Evaluation of a possible proximity effect of aspartame and vitamin C on muscular strength. | 2004-02 |
|
| Position of the American Dietetic Association: use of nutritive and nonnutritive sweeteners. | 2004-02 |
|
| The combination effect of L-arginine and NaCl on bitterness suppression of amino acid solutions. | 2004-02 |
|
| Intercalation of amino acids and peptides into Mg-Al layered double hydroxide by reconstruction method. | 2004-01-28 |
|
| Behavioral study in the gray mouse lemur (Microcebus murinus) using compounds considered sweet by humans. | 2004-01 |
|
| Influence of repeated consumption of beverages containing sucrose or intense sweeteners on food intake. | 2004-01 |
|
| Aspartame disease: a possible cause for concomitant Graves' disease and pulmonary hypertension. | 2004 |
|
| Systemic contact dermatitis of the eyelids caused by formaldehyde derived from aspartame? | 2003-11 |
|
| Construction of hybrid peptide synthetases for the production of alpha-l-aspartyl-l-phenylalanine, a precursor for the high-intensity sweetener aspartame. | 2003-11 |
|
| Wants to clear up Internet misinformation regarding aspartame. | 2003-08-01 |
|
| An intermediate in a new synthesis approach to beta-substituted beta-hydroxyaspartame. | 2003-08 |
|
| [Development of an optimized formulation of damask marmalade with low energy level using Taguchi methodology]. | 2003-06 |
|
| Headspace solid-phase micro-extraction gas chromatography method for the determination of methanol in aspartame sweeteners. | 2003-06 |
|
| Taste perception with age: generic or specific losses in supra-threshold intensities of five taste qualities? | 2003-06 |
|
| Electrochemical study of the complexes of aspartame with Cu(II), Ni(II) and Zn(II) ions in the aqueous medium. | 2003-05-23 |
|
| The powder flow and compact mechanical properties of sucrose and three high-intensity sweeteners used in chewable tablets. | 2003-05-12 |
|
| Effects of sugar intake on body weight: a review. | 2003-05 |
|
| Physiological mechanisms mediating aspartame-induced satiety. | 2003-04 |
|
| Comparison of the responses of the chorda tympani and glossopharyngeal nerves to taste stimuli in C57BL/6J mice. | 2003-03-04 |
|
| Discovery and structure determination of a novel Maillard-derived sweetness enhancer by application of the comparative taste dilution analysis (cTDA). | 2003-02-12 |
|
| Estimated intake of the artificial sweeteners acesulfame-K, aspartame, cyclamate and saccharin in a group of Swedish diabetics. | 2003-02 |
|
| Possible pathomechanism of autoimmune hepatitis. | 2003-01-11 |
|
| Formaldehyde-induced shrinkage of rat thymocytes. | 2003-01 |
|
| The diet factor in pediatric and adolescent migraine. | 2003-01 |
|
| [Controversies with aspartame]. | 2003 |
|
| The effect of various substances on the suppression of the bitterness of quinine-human gustatory sensation, binding, and taste sensor studies. | 2002-12 |
|
| Modified DNA aptamers against sweet agent aspartame. | 2002 |
|
| [Simultaneous determination of various food additives by high performance liquid chromatography]. | 2001-03 |
|
| One on one. Is aspartame safe to use? | 2001-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11372003
23 subjects from the Sickle Cell Clinic (University of Oklahoma Health Sciences Center, Oklahoma City, Okla) consented to participate in a randomized single-dose administration of 1.5, 3.0, or 6 mg/kg aspartame.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11372003
For the in vitro studies, blood from 20 subjects monitored for sickle cell anemia was collected in heparinized tubes. Specimens were divided in thirds and aspartame was added to 2 tubes to yield a 1 mg/mL or 2 mg/mL concentration. Sickled cells that were present after a drop from each aliquot was added to a fresh 2% metabisulfite solution were counted 3 times. For the in vitro studies, sickled cells decreased from 28% to < 14% when 1 mg/mL aspartame was added and decreased further with 2 mg/mL.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:35:25 GMT 2025
by
admin
on
Wed Apr 02 08:35:25 GMT 2025
|
| Record UNII |
Z0H242BBR1
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 201.66
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
||
|
NCI_THESAURUS |
C283
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-951
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
||
|
CFR |
21 CFR 172.804
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
||
|
CFR |
21 CFR 201.21
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
||
|
DSLD |
1055 (Number of products:1)
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
||
|
JECFA EVALUATION |
INS-951
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1043706
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
E-951
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
134601
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
758953
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
22839-47-0
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
Aspartame
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
DB00168
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
3019
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
245-261-3
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
CHEMBL171679
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
m2099
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | Merck Index | ||
|
Z0H242BBR1
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
DTXSID0020107
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
D001218
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
C76513
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
100000139218
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
Z0H242BBR1
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
2877
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
1311524
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB84574
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
3915
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY | |||
|
ASPARTAME
Created by
admin on Wed Apr 02 08:35:25 GMT 2025 , Edited by admin on Wed Apr 02 08:35:25 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
||
|
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |